New insider activity at Keros Therapeutics ( (KROS) ) has taken place on October 17, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Significant shareholder Pontifax Management 4 G.P. (2015) Ltd. has made a substantial move by selling 4,787,331 shares of Keros Therapeutics stock. This transaction is valued at an impressive $84,975,125.
Recent Updates on KROS stock
In the last 24 hours, Keros Therapeutics announced a $375 million capital return program, including a significant share repurchase from ADAR1 Capital Management and Pontifax Venture Capital, which underscores the company’s confidence in its financial health and clinical strategy, particularly for its KER-065 program. The company also plans to distribute part of its Takeda licensing revenue to shareholders, aiming to boost long-term stockholder value. Additionally, there were changes in the board of directors, with new appointments reflecting a strategic shift. Analysts have maintained a Hold rating on the stock, citing strong financial performance but cautioning about potential overvaluation due to a high P/E ratio and mixed technical indicators.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
Keros Therapeutics’ overall score is driven by its strong financial performance, particularly its profitability and balance sheet strength. However, technical indicators suggest mixed signals, and the high P/E ratio indicates potential overvaluation. The absence of earnings call data and corporate events limits further insights.
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
YTD Price Performance: -13.69%
Average Trading Volume: 544,938
Technical Sentiment Signal: Sell
Current Market Cap: $558.1M